Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Study Finds Contrasting Genomic Profiles Among Tissue Samples, Liquid Biopsies of Prostate Cancer
August 25th 2021The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.
Patients, Caregivers Report Lack of Supportive Services for Inherited Metabolic Diseases
August 25th 2021The European-based survey collected information from over 900 patients and caregivers from 25 countries; the responses show a need for both local and national governments to scale up their services for patients with rare metabolic diseases, which also have a positive spillover effects for caregivers.
Meta-Analysis Highlights Promising Efficacy, Safety of Approved CAR T-Cell Products
August 23rd 2021Researchers found the 3 treatments—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel (liso-cel)—showed promising efficacy and safety results across histological types, although they noted a need for more real-world data to validate the efficacy of liso-cel.
AML Treatment Improves Complete Remission, Total Effectiveness Rates
August 23rd 2021The researchers of a new analysis argue that the treatments they investigated for acute myelogenous leukemia (AML) are worthy of clinical promotion based on their findings, which they say also provide evidence-based guidance for clinical practice.
Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients
August 13th 2021Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.
Researchers Highlight Delivery of CAR T-Cell Therapy Through Modified AAV
August 11th 2021In a preclinical study, researchers were able to show that their modified adeno-associated virus (AAV) vector safely delivered the chimeric antigen receptor (CAR) gene into the host cells and produced enough CAR T cells to cause effective tumor regression and elicit antitumor immunological characteristics in a mouse model of human T-cell leukemia.
Meta-Analysis Finds CIT Regimens Associated With Improved Survival, Safety Outcomes in NSCLC
August 11th 2021Due to the lack of head-to-head trials comparing chemoimmunotherapy regimens with chemotherapy alone as first-line treatment for non-small cell lung cancer, researchers conducted a network meta-analysis of 17 randomized controlled trials of patients with the cancer.
Review Determines Cost-effectiveness of Precision Diagnostic Testing in NSCLC
August 7th 2021The analysis included 64 cost-effectiveness analysis scenarios across more than 30 studies between 2009 and 2019, approximately half (53%) of which determined precision diagnostic testing to be cost-effective.
MHC-II May Be Predictor of Immunotherapy Response in HR+, Triple-Negative Breast Cancers
August 6th 2021The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in these patients.
Immunotherapy Tops Chemotherapy for Improving Outcomes in Real-World Study of Merkel Cell Carcinoma
July 23rd 2021Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).
Real-world Data Show Higher Incidence of Neutropenia With Venetoclax, Obinutuzumab Combo in CLL
July 22nd 2021Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).
Receiving Ruxolitinib Post Transplant Improves Survival Among Patients With Myelofibrosis
July 22nd 2021A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.
Number of Plasma Variants Associated With Lung Cancer Survival, Says Liquid Biopsy Analysis
July 18th 2021Researchers have found that the number of variants a patient had in their plasma had prognosis implications, with circulating cell-free DNA mutational load having a significant association with overall survival.
Researchers Outline Ongoing Studies, Challenges of CAR T-Cell Therapy in GBM
July 16th 2021Although there is hope chimeric antigen receptor (CAR) T-cell therapy can revolutionize how to treat glioblastoma multiforme (GBM), there is still more research to be done, say investigators, noting that research on CAR T-cell therapy in this setting is still in early stages.